Potential Effects of Essential Oil from IPlinia cauliflora/I Kausel on ILeishmania/I: In Vivo, In Vitro, and In Silico Approaches

• Published in: Microorganisms (Basel) 2024-01, Vol.12 (1)
• Main Authors: Holanda, Vanderlan N, Brito, Thaíse G. S, Oliveira, João R. S. de, Cunha, Rebeca X. da, Silva, Ana P. S. da, Silva, Welson V. da, Araújo, Tiago F. S, Tavares, Josean F, Santos, Sócrates G. dos, Figueiredo, Regina C. B. Q, Lima, Vera L. M
• Format: Article
• Language: English
• Subjects: Control; Essences and essential oils; Health aspects; Leishmania; Medicinal plants; Myrtaceae
• ISSN: 2076-2607; 2076-2607
• DOI: 10.3390/microorganisms12010207

In the search for new chemotherapeutic alternatives for cutaneous leishmaniasis (CL), essential oils are promising due to their diverse biological potential. In this study, we aimed to investigate the chemical composition and leishmanicidal and anti-inflammatory potential of the essential oil isolated from the leaves of Plinia cauliflora (PCEO). The chemical composition of PCEO showed β-cis-Caryophyllene (24.4%), epi-γ-Eudesmol (8%), 2-Naphthalenemethanol[decahydro-alpha] (8%), and trans-Calamenene (6.6%) as its major constituents. Our results showed that the PCEO has moderate cytotoxicity (CC[sub.50] ) of 137.4 and 143.7 μg/mL on mice peritoneal exudate cells (mPEC) and Vero cells, respectively. The PCEO was able to significantly decrease mPEC infection by Leishmania amazonensis and Leishmania braziliensis. The value of the inhibitory concentration (IC[sub.50] ) on amastigote forms was about 7.3 µg/mL (L. amazonensis) and 7.2 µg/mL (L. braziliensis). We showed that PCEO induced drastic ultrastructural changes in both species of Leishmania and had a high selectivity index (SI) > 18. The in silico ADMET analysis pointed out that PCEO can be used for the development of oral and/or topical formulation in the treatment of CL. In addition, we also demonstrated the in vivo anti-inflammatory effect, with a 95% reduction in paw edema and a decrease by at least 21.4% in migration immune cells in animals treated with 50 mg/kg of PCEO. Taken together, our results demonstrate that PCEO is a promising topical therapeutic agent against CL.